VALUTAZIONE DELL'AGGREGAZIONE PIASTRINICA DI ALCUNI PARAMETRI EMOCOAGULATIVI E DEL PROFILO LIPIDICO IN PAZIENTI TRATTATI CON SULOCTIDIL

Translated title of the contribution: Evaluation of platelet aggregation, some blood clotting parameters, and the lipid profile in patients treated with Suloctidyl

G. Palmieri, M. Perego, I. M. Baldini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A double-blind clinical trial (Suloctidyl versus placebo) was carried out to determine changes in platelet aggregation, anti-thrombin III, partial thromboplastin time, triglycerides, cholesterol, and HDL cholesterol induced by 300 mg/day active principle for 30 days in 40 patients with coronary, peripheral, and cerebral atherosclerosis and hyperlipoproteinaemia. The drug led to a decrease in platelet aggregation, and a positive change in the HDL:LDL (antiatherogen:atherogen) ratio, but did not alter antithrombin III or the partial thromboplastin time.

Original languageItalian
Pages (from-to)143-152
Number of pages10
JournalGazzetta Medica Italiana
Volume141
Issue number4
Publication statusPublished - 1982

Fingerprint

Partial Thromboplastin Time
Blood Coagulation
Platelet Aggregation
Intracranial Arteriosclerosis
Lipids
Hyperlipoproteinemias
Antithrombin III
Thrombin
HDL Cholesterol
Coronary Artery Disease
Triglycerides
Cholesterol
Placebos
Clinical Trials
Pharmaceutical Preparations
low density lipoprotein inhibitor

ASJC Scopus subject areas

  • Medicine(all)

Cite this

VALUTAZIONE DELL'AGGREGAZIONE PIASTRINICA DI ALCUNI PARAMETRI EMOCOAGULATIVI E DEL PROFILO LIPIDICO IN PAZIENTI TRATTATI CON SULOCTIDIL. / Palmieri, G.; Perego, M.; Baldini, I. M.

In: Gazzetta Medica Italiana, Vol. 141, No. 4, 1982, p. 143-152.

Research output: Contribution to journalArticle

@article{01122c093a2a471da3ee03a7ee10156f,
title = "VALUTAZIONE DELL'AGGREGAZIONE PIASTRINICA DI ALCUNI PARAMETRI EMOCOAGULATIVI E DEL PROFILO LIPIDICO IN PAZIENTI TRATTATI CON SULOCTIDIL",
abstract = "A double-blind clinical trial (Suloctidyl versus placebo) was carried out to determine changes in platelet aggregation, anti-thrombin III, partial thromboplastin time, triglycerides, cholesterol, and HDL cholesterol induced by 300 mg/day active principle for 30 days in 40 patients with coronary, peripheral, and cerebral atherosclerosis and hyperlipoproteinaemia. The drug led to a decrease in platelet aggregation, and a positive change in the HDL:LDL (antiatherogen:atherogen) ratio, but did not alter antithrombin III or the partial thromboplastin time.",
author = "G. Palmieri and M. Perego and Baldini, {I. M.}",
year = "1982",
language = "Italian",
volume = "141",
pages = "143--152",
journal = "Gazzetta Medica Italiana Archivio per le Scienze Mediche",
issn = "0393-3660",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - VALUTAZIONE DELL'AGGREGAZIONE PIASTRINICA DI ALCUNI PARAMETRI EMOCOAGULATIVI E DEL PROFILO LIPIDICO IN PAZIENTI TRATTATI CON SULOCTIDIL

AU - Palmieri, G.

AU - Perego, M.

AU - Baldini, I. M.

PY - 1982

Y1 - 1982

N2 - A double-blind clinical trial (Suloctidyl versus placebo) was carried out to determine changes in platelet aggregation, anti-thrombin III, partial thromboplastin time, triglycerides, cholesterol, and HDL cholesterol induced by 300 mg/day active principle for 30 days in 40 patients with coronary, peripheral, and cerebral atherosclerosis and hyperlipoproteinaemia. The drug led to a decrease in platelet aggregation, and a positive change in the HDL:LDL (antiatherogen:atherogen) ratio, but did not alter antithrombin III or the partial thromboplastin time.

AB - A double-blind clinical trial (Suloctidyl versus placebo) was carried out to determine changes in platelet aggregation, anti-thrombin III, partial thromboplastin time, triglycerides, cholesterol, and HDL cholesterol induced by 300 mg/day active principle for 30 days in 40 patients with coronary, peripheral, and cerebral atherosclerosis and hyperlipoproteinaemia. The drug led to a decrease in platelet aggregation, and a positive change in the HDL:LDL (antiatherogen:atherogen) ratio, but did not alter antithrombin III or the partial thromboplastin time.

UR - http://www.scopus.com/inward/record.url?scp=0020324693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020324693&partnerID=8YFLogxK

M3 - Articolo

VL - 141

SP - 143

EP - 152

JO - Gazzetta Medica Italiana Archivio per le Scienze Mediche

JF - Gazzetta Medica Italiana Archivio per le Scienze Mediche

SN - 0393-3660

IS - 4

ER -